Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia

Status: Completed

Protocol number: WI18273

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: A randomized, double-blind study of the effect of beta-lactam on treatment response in patients hospitalized with bacterial pneumonia

Brief summary: This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals. Target sample size is 300.

Study phase: II

Study type: Interventional; Treatment; Randomized; Double Blind; Active; Parallel; Safety/Efficacy study

Condition: Pneumonia, Bacterial

Intervention type: Drug

Intervention name: Beta-Lactam

Primary outcome: 1. Clinical cure rate Time frame: End of study visit (7-10 days after end of treatment)

Key secondary outcomes: 1. Adverse events, vital signs, laboratory parameters Time frame: Throughout study

Inclusion criteria:

  • male or female patients at least 18 years of age;
  • hospitalization with community-acquired pneumonia or development of pneumonia within 48 hours of being hospitalized for another reason;
  • fever;
  • new or increased productive cough;
  • chest pain, shortness of breath, or rapid breathing.

Exclusion criteria:

  • requiring intubation or ventilation;
  • nursing home or extended care within 60 days before study;
  • concomitant bacterial infection requiring antibiotics;
  • long-term immunosuppressive therapy.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Trial registration date: 07/26/2005

Date last updated: 11/19/2009


Link to trial result

This trial was conducted at the following locations:

Argentina

  • Buenos Aires
  • Ciudadela
  • Córdoba
  • Granadero Baigorria
  • Parana
  • Rosario

Bulgaria

  • Ruse
  • Sofia

Chile

  • Santiago
  • Valdivia

Croatia

  • Zagreb

Hungary

  • Budapest
  • Nyiregyhaza
  • Torokbalint
  • Zalaegerszeg

Latvia

  • Daugavpils
  • Riga

Lithuania

  • Kaunas
  • Klaipeda
  • Vilnius

Peru

  • Lima

Romania

  • Bucharest
  • Constanta
  • Craiova

Slovakia

  • Banska Bystrica
  • Nitra
  • Poprad

United States

  • New Orleans, LA
  • Shreveport, LA
  • Detroit, MI
  • Butte, MT
  • Holmdel, NJ
  • Winston-Salem, NC

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply